Figures & data
Figure 1 The efficacy outcome at the end of 6 weeks of treatment of acutely depressed type I bipolar patients treated with placebo, or monotherapy with lurasidone 20–60 mg/day, or lurasidone 80–120 mg/day.
Abbreviation: MADRS, Montgomery–Ȧsberg Depression Rating Scale.
![Figure 1 The efficacy outcome at the end of 6 weeks of treatment of acutely depressed type I bipolar patients treated with placebo, or monotherapy with lurasidone 20–60 mg/day, or lurasidone 80–120 mg/day.](/cms/asset/2e1d34b4-bf4c-4299-81e1-deced29ac656/dtcr_a_57695_f0001_c.jpg)
Figure 2 The efficacy outcome at the end of 6 weeks of treatment of acutely depressed type I bipolar patients treated with lithium or valproate to which either placebo was added or lurasidone 20–80 mg/day.
Abbreviations: Li, lithium; VPA, valproate; MADRS, Montgomery–Ȧsberg Depression Rating Scale.
![Figure 2 The efficacy outcome at the end of 6 weeks of treatment of acutely depressed type I bipolar patients treated with lithium or valproate to which either placebo was added or lurasidone 20–80 mg/day.](/cms/asset/a8fefe67-297d-4146-95c8-fa23a215c704/dtcr_a_57695_f0002_c.jpg)
Table 1 Spontaneously reported adverse events (AEs) in the three registrational trials for lurasidone